Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case

Jaclyn J Renfrow1, Alisha Detroye, Michael Chan

  • 1Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.

Journal of Neuro-Oncology
|January 18, 2012
PubMed
Summary

Bendamustine shows promise for recurrent primary central nervous system lymphoma (RPCNSL). This therapy was well-tolerated, with one patient achieving stable disease for over 20 months post-treatment.